Skip to content

Vera Therapeutics VERA Accrued Liabilities, Current

Accrued Liabilities, Current at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
Johnson & Johnson logo
Johnson & JohnsonJNJ

Other financials

Income statement

See full
Operating income-$125.1M-119%
Net income-$121.0M-134%
EPS (diluted)-$1.69-109%

Balance sheet

See full
Cash & equivalents$114.4M+108%
Total debt$75.0M+37.8%
Total equity$499.7M-6.6%
Total assets$621.7M+1.9%

Cash flow

See full
Operating cash flow-$106.5M-95.8%
CapEx$23.0K-87.7%
Free cash flow-$106.5M-95.1%

Valuation

See full
Market cap$2.74B+87.5%
Enterprise value$2.7B+85.0%

Returns & leverage

See full
Return on equity-71.3%+296pp
Debt / equity0.2×0.0×
Current ratio13.6×-14.0×

Where this comes from

Reported directly by Vera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Vera Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vera Therapeutics's accrued liabilities, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vera Therapeutics's accrued liabilities, current?
Vera Therapeutics (VERA) reported accrued liabilities, current of $31.24M in Q1 2026.
How has Vera Therapeutics's accrued liabilities, current changed year-over-year?
Vera Therapeutics's accrued liabilities, current increased by 173.1% year-over-year, from $11.44M to $31.24M.
What is the long-term trend for Vera Therapeutics's accrued liabilities, current?
Over 5 years (2020 to 2025), Vera Therapeutics's accrued liabilities, current has grown at a 126.0% compound annual growth rate (CAGR), from $535K to $31.56M.